Quantcast

Latest Epidermal growth factor receptor Stories

2008-08-28 09:01:23

The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities. The electrical impedance detection method with Roche's real-time cell microelectronic sensor-based platform xCELLigence system is a facile, high content, and cell based kinase assay allowing for monitoring short term RTK activation...

2008-08-26 09:01:20

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2) and histone deacetylase (HDAC). CUDC-101 has been designed to simultaneously...

2008-08-04 21:00:07

MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The trial was conducted at 10 centres across...

2008-07-14 09:00:14

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

2008-07-07 09:00:16

* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the...

2008-07-02 12:01:11

Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer. In colorectal cancers, EGF-receptors transmit a series of signals through a complex path of intracellular proteins. These signals ultimately instruct the cancer cell to undergo a transcription process leading to cancer progression. Anti-EGF-receptor therapies such as panitumumab and cetuximab work by...

2008-06-30 12:03:15

Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan. Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human...

2008-06-24 02:30:29

SOUTH SAN FRANCISCO, Calif., June 23, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it will present pre-clinical data on Menadione Topical Lotion and clinical data on Alocrest(tm) (vinorelbine liposomes injection, OPTISOME(tm)) at the European Society for Medical Oncology (ESMO) Conference taking place July 3-6, 2008 in Lugano, Switzerland. Menadione is a topical agent that Hana...

2008-03-05 09:01:06

Response Genetics, Inc. (NASDAQ: RGDX) announced today that its ResponseDX: Lung™ and ResponseDX: Colon™ tests are now available to select medical institutions and practice groups through its CLIA-registered laboratory. ResponseDX: Lung™ and ResponseDX: Colon™ are PCR-based tests that help guide therapeutic treatment decisions in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The tests are in their initial launch phase and are...

2008-01-16 03:00:13

By Yip, Stephen Iafrate, A John; Louis, David N Abstract Advances in understanding the molecular underpinnings of cancer and in molecular diagnostic technologies have changed the clinical practice of oncologic pathology. The development of targeted therapies against specific molecular alterations in cancer further portends changes in the role of the pathology laboratory to guide such custom therapies. To reconcile the flood of scientific discoveries in this area, the promises of highly...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related